Dataset: Evaluation of recombinant monoclonal antibody SVmab1 binding to NaV1.7 target sequences and block of human NaV1.7 currents ------------------------------------------------------------------------ **Abstract** Identification of small and large molecule pain therapeutics that target the genetically validated voltage-gated sodium channel NaV1.7 is a challenging endeavor under vigorous pursuit. The monoclonal antibody SVmab1 was recently published to bind the NaV1.7 DII voltage sensor domain and block human NaV1.7 sodium currents in heterologous cells. We produced purified SVmab1 protein based on publically available sequence information, and evaluated its activity in a battery of binding and functional assays. Herein, we report that our recombinant SVmAb1 does not bind peptide immunogen or purified NaV1.7 DII voltage sensor domain via ELISA, and does not bind NaV1.7 in live HEK293, U-2 OS, and CHO-K1 cells via FACS. Whole cell manual patch clamp electrophysiology protocols interrogating diverse NaV1.7 gating states in HEK293 cells, revealed that recombinant SVmab1 does not block NaV1.7 currents to an extent greater than observed with an isotype matched control antibody. Collectively, our results show that recombinant SVmab1 monoclonal antibody does not bind NaV1.7 target sequences or specifically inhibit NaV1.7 current. Read the [full-text publication][1] by Dong Liu et al. (*F1000Research*, 2016) for more details. **Data availability** [Dataset 1: Figure 3 raw data (peptide ELISA). ][2]\ [Dataset 2: Figure 4 raw data (D2S ELISA).][3] \ [Dataset 3: Figure 5 raw data (FACS binding).][4]\ [Dataset 4: Figure 6 raw data (e-phys 100nM rSVmab1).][5]\ [Dataset 5: Figure 7 raw data (e-phys 500nM rSVmab1).][6]\ [Dataset 6: Figure 8 raw data (e-phys inactivation 500nM rSVmab1).][7]\ [Dataset 7: Figure 9 raw data (e-phys use-dpendence 500 nM rSVmab1).][8]\ [Dataset 8: Figure 10 raw data (e-phys partial inactivation 500 nM rSVmab1).][9]\ [Dataset 9: Figure 11 raw data (e-phys slow inactivation and use-dependence 500 nM rSVmab1).][10] [1]: http://dx.doi.org/10.12688/f1000research.9957.1 [2]: https://osf.io/2cb9d/ [3]: https://osf.io/s29tb/ [4]: https://osf.io/b2hg7/ [5]: https://osf.io/c97ak/ [6]: https://osf.io/5kqy3/ [7]: https://osf.io/my55d/ [8]: https://osf.io/9fbf9/ [9]: https://osf.io/xw23h/ [10]: https://osf.io/n3x9v/